Open-label, intermittent dose, prospective study evaluating the effects of tadalafil on lower urinary tract symptoms and erectile function in patients with benign prostatic hyperplasia: Continuation and durability of effects

International Neurourology Journal

Volumn 14, Issue 1, 2010, Pages 7-12

  Kim, Tae Beom ^a   Kim, Khae Hawn ^a   Yoon, Sang Jin ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Benign; Erectile dysfunction; Tadalafil

Indexed keywords

EID: 79960973872     PISSN: 20934777     EISSN: 20936931     Source Type: Journal    
DOI: 10.5213/inj.2010.14.1.7     Document Type: Article

References (25)

1. Calais DS, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997;31:272-80
2. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000;56:3-6
3. Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G. The long-term outcome of medical therapy for BPH. Eur Urol 2007;51:1522-33
4. Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006;7:288-92
5. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006; 3:676-81
6. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166:2484-90
7. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006;49: 740-5
8. Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007;19:139-48
9. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. JSex Med 2006;3:883-91
10. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossoverstudy. J Sex Med 2006; 3:1037-49
11. Padma-Nathan H. PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy. Rev Urol 2005;7 Suppl 2:S33-8
12. Aversa A, Bruzziches R, Pili M, Spera G. Phosphodie- sterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006;12: 3467-84
13. Christiansen E, Guirguis WR, Cox D, Osterloh IH. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000;12:177-82
14. McMahon CG. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol 2006;50: 215-7
15. Sommer F, Klotz T, Engelmann U. Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J Androl 2007;9:134-41
16. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005;47:214-20
17. Sommer F, Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhi- bitors. World J Urol 2005;23:385-92
18. Porst H, Giuliano F, Glina S, Ralph D, Casabe AR, Elion-Mboussa A et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:351-9
19. Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 2006;38:S2-6
20. Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003;35:207
21. Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van Ahlen H et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 2005;47:846-54
22. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98:1259-63
23. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-29
24. McVary KT, Monnig W, Camps JL, Jr., Young JM, Tseng LJ, van den EG. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177:1071-7
25. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7